Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma.
- Author:
Weiping LIU
1
;
Xiaopei WANG
;
Chen ZHANG
;
Yan XIE
;
Ningjing LIN
;
Meifeng TU
;
Lingyan PING
;
Zhitao YING
;
Lijuan DENG
;
Huiying HUANG
;
Meng WU
;
Yingli SUN
;
Tingting DU
;
Xin LENG
;
Ning DING
;
Wen ZHENG
;
Yuqin SONG
;
Jun ZHU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; diagnosis; Middle Aged; Prednisone; Prognosis; Retrospective Studies; Rituximab; Vincristine; Young Adult
- From: Chinese Journal of Hematology 2016;37(4):269-272
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the prognostic value of different models in patients with early-stage diffuse large B-cell lymphoma (DLBCL).
METHODSEarly-stage DLBCL patients diagnosed from January 2000 to December 2012 were analyzed retrospectively. All patients received with at least 2 cycles of immunochemotherapy R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) with or without radiotherapy. The prognostic value of international prognostic index (IPI) , revised IPI (R-IPI) and enhanced IPI (NCCN-IPI) was compared.
RESULTSNinety-seven cases of early-stage DLBCL were included in the study. The median age was 58 years (15-88 years) with a median follow-up of 34.7 months (range 7.3-77.4 months). The expected 5-year overall survival (OS) for entire group was 82%. There was no patient in the high risk group according to IPI or NCCN-IPI. According to IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 95%, 38% and 60%, respectively. According to R-IPI, the 5-year OS in the very good, good, and poor risk groups were 93%, 75% and 60%, respectively. According to NCCN-IPI, the 5-year OS in the low, low intermediate, high intermediate risk groups were 92%, 85% and 29%, respectively.
CONCLUSIONNCCN-IPI would be of an ideal prognostic model for early-stage DLBCL patients.
